FDA’s new accelerated pathway may open pharma up to risks, as well as benefits
Written by
BioPharma Dive
Published
0
comments
0
min
Faster review times could leave drugmakers vulnerable to litigation, while new Trump administration priorities add more uncertainty to the drug approval process.